Want to take quizzes and track your credits?
Following massive global initiatives, the US Food and Drug Administration approved several SARS-CoV-2 vaccines, including the BNT162b2 (Pfizer-BioNTech) mRNA vaccine. While manifestations of COVID-19 are heterogeneous, patients with solid tumors undergoing active therapy are at considerable risk for worse outcomes.1,2 Among these patients, humoral response to SARS-CoV-2 vaccines has been reported in approximately 90%.3 Although high, this proportion is considerably lower than the 99% to 100% found in control groups.4 Among patients who are treated with chemotherapy, further reduced humoral responses have been described.3
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accepted for Publication: October 15, 2021.
Published Online: November 23, 2021. doi:10.1001/jamaoncol.2021.6764
Corresponding Author: Albert Grinshpun, MD, MSc, Breast Oncology Center, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215 (email@example.com).
Author Contributions: Drs Rottenberg and Grinshpun had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Rottenberg and Grinshpun served as co–first authors.
Concept and design: Grinshpun, Kadouri.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Rottenberg, Grinshpun, Oiknine Djian, Kadouri.
Critical revision of the manuscript for important intellectual content: Grinshpun, Ben-Dov, Wolf, Kadouri.
Statistical analysis: Ben-Dov.
Administrative, technical, or material support: Grinshpun, Oiknine Djian, Wolf, Kadouri.
Supervision: Rottenberg, Kadouri.
Conflict of Interest Disclosures: Dr Grinshpun reported support from the Israel Science Foundation (grant 3020/20) and the 2020 Conquer Cancer Israel Cancer Research Fund Career Development Award. Dr Kadouri reported support from Eli Lilly outside the submitted work. No other disclosures were reported.
Additional Contributions: We would like to thank all of the patients in this study as well as Miri Shapira from the Sharett Institute of Oncology at Hadassah Medical Center for her kind assistance in samples collection. Ms Shapira was compensated for her contributions.
You currently have no searches saved.
You currently have no courses saved.